TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00682214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose placebo
Description: Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Study: NCT02555020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Allocated to Carbohydrated group
Description: Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
Study: NCT02396316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, BAY 86-5321)
Description: After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
Study: NCT02555020

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Allocated to Placebo group
Description: Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allocated to MN NPO group,
Description: Patients received NPO from MN.
Study: NCT04352465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
Study: NCT03974750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual motor skill learning with the REAplan(R) rehabilitation robot
Description: REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bimanual motor skill learning with the REAplan(R) rehabilitation robot
Description: REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
Study: NCT03801421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mass continous suture with PDS
Description: The surgical incision will be treated by mass continous suture with PDS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture with thread
Description: The surgical incision will be treated by interrupted suture with thread.
Study: NCT03475264

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI
Description: Participants will be undergoing hyperpolarized xenon and proton lung MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI
Description: Participants will be undergoing hyperpolarized xenon and proton lung MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI
Description: Participants will be undergoing hyperpolarized xenon and proton lung MRI
Study: NCT03339505

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salovum
Description: Dietary supplement with high concentration of anti-secretory factor

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Salovum
Study: NCT03632967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricinch Coil System Implantation
Description: Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
Study: NCT05106543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients
Description: Kinesiological Taping

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients
Description: Kinesiological Taping
Study: NCT01727986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
Study: NCT01973023

Intervention type: OTHER
Intervention: Motion analysis
Description: Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
Study: NCT03650959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of learning simple interrupted sutures with instrument tie
Description: Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of learning simple interrupted sutures with instrument tie
Description: Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of learning simple interrupted sutures with instrument tie
Description: Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
Study: NCT02168725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: briciclib
Study: NCT03030716

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 95% condensed proanthocyanidins from grape seed extract
Description: 0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 95% condensed proanthocyanidins from grape seed extract
Description: 0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 95% condensed proanthocyanidins from grape seed extract
Description: 0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
Study: NCT03415984

Intervention type: DIAGNOSTIC_TEST
Intervention: Color retinography
Description: Color retinography

Intervention type: DIAGNOSTIC_TEST
Intervention: Color retinography
Description: Color retinography
Study: NCT03399448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Description: Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Description: Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: a chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: a chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: a chemotherapy agent used for lymphodepletion prior to NYCE T cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 expression testing
Description: Testing to determine if NY-ESO-1 is expressed on tumor tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 expression testing
Description: Testing to determine if NY-ESO-1 is expressed on tumor tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 expression testing
Description: Testing to determine if NY-ESO-1 is expressed on tumor tissue.
Study: NCT00140140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Weekly intravenous infusions over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Weekly intravenous infusions over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Weekly intravenous infusions over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
Study: NCT00718848

Intervention type: PROCEDURE
Intervention: Incentre nocturnal hemodialysis
Description: This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.

Intervention type: PROCEDURE
Intervention: Remaining on conventional hemodialysis
Description: These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
Study: NCT03160599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
Study: NCT03803605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR)
Description: Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
Study: NCT00140140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor.
Study: NCT03618524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb hot water immersion
Description: Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
Study: NCT05052450

Intervention type: OTHER
Intervention: Observational
Description: Patients data were collected throughout the following time
Study: NCT00140140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor.
Study: NCT03415984

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Optical coherence tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Optical coherence tomography
Study: NCT03090373

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: UroShield
Description: The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroShield
Description: The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
Study: NCT01831206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking
Description: Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication.
Study: NCT02129335

Intervention type: OTHER
Intervention: stress
Description: stress level and survival
Study: NCT00513097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Program
Description: Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: On-line evaluations and questionnaires
Study: NCT00574496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mechlorethamine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study: NCT05052450

Intervention type: OTHER
Intervention: Observational
Description: Patients data were collected throughout the following time

Intervention type: OTHER
Intervention: Observational
Description: Patients data were collected throughout the following time

Intervention type: OTHER
Intervention: Observational
Description: Patients data were collected throughout the following time

Intervention type: OTHER
Intervention: Observational
Description: Patients data were collected throughout the following time
Study: NCT03084744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema therapy
Description: Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active monitoring
Description: Active tele-monitoring by clinical psychologists.
Study: NCT03762434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile application
Description: Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile application
Description: Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management.
Study: NCT03407131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint replacement surgery
Description: Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nail fixation
Description: Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
Study: NCT00596648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Capsules administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Capsules administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Capsules administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tablets administered orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tablets administered orally daily.
Study: NCT04484480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
Study: NCT02577419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Target Fortification

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Initial Concentration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Portagen Formula
Study: NCT01624844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geometrical calculation of dural sac volume
Description: Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
Study: NCT03891927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: extra virgin olive oil
Description: During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
Study: NCT03282786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide insufflation during colonoscopy
Description: Use of Carbon dioxide instead of air insufflation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide insufflation during colonoscopy
Description: Use of Carbon dioxide instead of air insufflation
Study: NCT02544152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 8 mcg administered orally twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Study: NCT02152813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TENS and Task-orientated training
Description: All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
Study: NCT00574496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate